Strength of weakness in molecular interactions: toward transient medicines in drug discovery.

Authors

Sten Ohlson

Published in

Drug discovery today. Pages 104816. Sep 25, 2026. Epub Sep 25, 2026.

Abstract

Biological systems are governed by a myriad of molecular interactions, many of which remain poorly recognized. Growing evidence suggests that transient interactions (K_diss >1 µM) dominate the interactome and are crucial for dynamic molecular networks. By contrast, drug discovery has largely focused on high-affinity compounds that bind strongly to their targets. Although this strategy has delivered many successful medicines, exploiting transient interactions can offer new therapeutic opportunities, particularly for complex diseases. Transient medicines are characterized by rapid binding kinetics, concentration-driven activity and the potential for multi-target and multivalent engagement. Recognizing transient interactions as functionally important rather than biological noise could expand the drug discovery design space and establish transient medicines as a complement to current therapeutic strategies.

PMID:
42790673
Bibliographic data and abstract were imported from PubMed on 26 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.